Cetera Investment Advisers
PACB icon

Cetera Investment Advisers’s Pacific Biosciences PACB Stock Holding History

Cetera Investment Advisers’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91.8K Buy
54,663
+3,304
+6% +$4.8K ﹤0.01% 4679
2026
Q1 		$67.8K Buy
51,359
+2,416
+5% +$4.32K ﹤0.01% 4538
2025
Q4 		$91.5K Sell
48,943
-101,238
-67% -$195K ﹤0.01% 4423
2025
Q3 		$192K Buy
150,181
+45,456
+43% +$61.6K ﹤0.01% 4163
2025
Q2 		$130K Buy
104,725
+9,617
+10% +$11.1K ﹤0.01% 3841
2025
Q1 		$112K Buy
95,108
+66,776
+236% +$102K ﹤0.01% 3752
2024
Q4 		$51.8K Sell
28,332
-91,167
-76% -$178K ﹤0.01% 3654
2024
Q3 		$203K Buy
119,499
+89,139
+294% +$146K ﹤0.01% 3372
2024
Q2 		$41.6K Sell
30,360
-11,157
-27% -$22.5K ﹤0.01% 3606
2024
Q1 		$156K Buy
41,517
+27,105
+188% +$159K ﹤0.01% 3417
2023
Q4 		$141K Buy
+14,412
New +$118K ﹤0.01% 2103

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cetera Investment Advisers's PACB Position: Q2 2026 in Review

Cetera Investment Advisers increased its Pacific Biosciences (PACB) stake by 6.4% in Q2 2026, buying an estimated $4.8K and bringing the position to 54,663 shares worth $91.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4679.

Cetera Investment Advisers first reported a position in PACB in Q4 2023 and has held it in 11 quarters since. The position peaked at $203K in Q3 2024. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Cetera Investment Advisers held 54,663 shares of Pacific Biosciences worth $91.8K as of Q2 2026.
  • Cetera Investment Advisers bought 3,304 Pacific Biosciences shares in Q2 2026, an estimated $4.8K.
  • Pacific Biosciences made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #4679 holding.
  • Cetera Investment Advisers first reported a position in Pacific Biosciences in Q4 2023 and has held it in 11 quarters since.
  • Cetera Investment Advisers's Pacific Biosciences position peaked at $203K in Q3 2024.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.